Home › Research › Clinical safety
A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy
EDUARDO S. TOLOSA, Irene Litvan, Günter U. Höglinger, David John Burn, Andrew John Lees, Maria Velasco de Andrés, Belén Gómez‐Carrillo, Teresa León et al.. Movement Disorders, 2014-02-14
Topic: Disease mechanisms in lab and animal studies
Plain-language summary
It is believed that glycogen synthase kinase-3 (GSK-3) hyperphosphorylates tau protein in progressive supranuclear palsy (PSP). The Tau Restoration on PSP (TAUROS) study was a double-blind, placebo-controlled, randomized trial to assess the efficacy, safety, and tolerability of tideglusib, a GSK-3 inhibitor, as potential treatment for PSP. The study enrolled 146 PSP patients with mild-to-moderate disease who were randomized to receive once-daily 600 mg tideglusib, 800 mg tideglusib, or placebo (ratio, 2:2:1) administered orally over 52 weeks. The primary endpoint was the change from baseline to week 52 on the PSP rating scale. Secondary endpoints were safety and tolerability of tideglusib, changes in motor function (the Timed Up and Go Test), cognition (Dementia Rating Scale-2, Frontal Assessment Battery, verbal fluency), apathy (Starkstein scale), activities of daily living (Schwab and England scale; Unified Parkinson's Disease Rating Scale, part II), quality of life (EuroQol), and Global Clinical Assessment. Brain atrophy on magnetic resonance imaging and several biomarkers in plasma and cerebrospinal fluid also were examined. No significant differences were detected in the primary or secondary endpoints at week 52 between placebo and either dose of tideglusib. Tideglusib was safe, with the exception of some asymptomatic, transient, and reversible transaminase elevations (mainly alanine aminotransferase) in 9% of patients, and diarrhea in 13% of patients. Tideglusib was generally well tolerated but it did not show clinical efficacy in patients with mild-to-moderate PSP.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
TOLOSA, E. S., Litvan, I., Höglinger, G. U., Burn, D. J., Lees, A. J., de Andrés, M. V., et al. (2014). A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy. Movement Disorders. https://doi.org/10.1002/mds.25824
Vancouver
TOLOSA ES, Litvan I, Höglinger GU, Burn DJ, Lees AJ, de Andrés MV, et al. A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy. Movement Disorders. 2014. doi:10.1002/mds.25824. PMID: 24532007.
BibTeX
@article{tolosa2014-24532007,
author = {TOLOSA, EDUARDO S. and Litvan, Irene and Höglinger, Günter U. and Burn, David John and Lees, Andrew John and de Andrés, Maria Velasco and Gómez‐Carrillo, Belén and León, Teresa and others},
title = {{A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy}},
journal = {Movement Disorders},
year = {2014},
doi = {10.1002/mds.25824},
pmid = {24532007},
url = {https://doi.org/10.1002/mds.25824}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- No significant differences were detected in the primary or secondary endpoints at week 52 between placebo and either dose of tideglusib.
Study details
- Study designrandomized controlled trial
- Participants146
- Evidence strengthHigh
How this study scored 76/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 44 of the 58 points we could judge it on, which is 76 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Movement Disorders) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomized controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2014 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 146 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 24532007) |
| Free to read | 2 / 2 | Free to read |
| Points | 44 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 44 of the 58 points we could judge it on is 76 out of 100. |
| Total | 76 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Clinical safety from nearby years
Also in Clinical safety
96 studies in the library are filed under Clinical safety with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Clinical safety hub.